close
 To:

From:

Current Advances

Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with hypertriglyceridemia

Isis announces the initiation of a Phase 2 study evaluating ISIS-APOCIIIRx in patients with hypertriglyceridemia. Hypertriglyceridemia, a condition characterized by high levels of triglycerides, is often associated with premature coronary artery disease and pancreatitis. Patients with severe hypertriglyceridemia often cannot control their triglyceride levels with existing medicines. ISIS-APOCIIIRx lowers triglycerides by reducing the protein, apoC-III. Both triglycerides and apoC-III are independent risk factors for cardiovascular disease.

Please see below to access the webcast, slides, press release and ACC poster.

Webcast »

Slide Deck »

Press Release »

ACC Poster »

About Isis

We know that sick people depend on us, and we have the technology to change the way diseases are treated.

Learn More

Mission & Values

Our mission is to provide antisense drugs to patients with significant unmet medical needs.

Learn More